Fenofibrate in Type 2 Diabetes

Medical University of South Carolina (MUSC)

Status and phase: Completed; Phase 4

Conditions: Diabetes Mellitus, Type II

Treatments: Drug: Fenofibrate

Study type: Interventional

Funder types: Other

Identifiers

NCT03829514

Pro00079289

Details and patient eligibility

About

Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.

Enrollment: 10 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes of at least one year's duration; stable glycemic control (no more than 1.0% change in HbA1c in the previous six months, but no limit on HbA1c)
• Triglycerides >150 mg/dL (in the previous six months)

Exclusion criteria

• Previous use of Fenofibrate or other fibrates
• Pregnancy
• Active malignancy
• Recent cardiac event or congestive heart failure
• Active liver disease
• Significant renal impairment (serum creatinine > 2mg/dl)

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Fenofibrate

Experimental group

Description:

Single arm. Participants will take study medication

Treatment:

Drug: Fenofibrate